Comera Life Sciences Inc...
(CMRA)
undefined
undefined%
At close: undefined
Company Description
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore.
Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications.
Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Comera Life Sciences Inc.
| Country | United States |
| IPO Date | Dec 21, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Michael G. Campbell CPA |
Contact Details
Address: 12 Gill Street Woburn, Massachusetts United States | |
| Website | https://comeralifesciences.com |
Stock Details
| Ticker Symbol | CMRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001907685 |
| CUSIP Number | 20037C108 |
| ISIN Number | US20037C1080 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael G. Campbell CPA | Chief Executive Officer, Chief Financial Officer & Principal Accounting Officer |
| Dr. David Soane Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Janice Marie McCourt B.S., CLP, M.B.A., R.Ph. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 26, 2024 | S-8 POS | Filing |
| Feb 26, 2024 | S-8 POS | Filing |
| Feb 26, 2024 | S-8 POS | Filing |
| Feb 26, 2024 | POS AM | Filing |
| Feb 26, 2024 | POS AM | Filing |
| Feb 26, 2024 | POS AM | Filing |
| Feb 26, 2024 | POS AM | Filing |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 15, 2024 | 25-NSE | Filing |
| Feb 02, 2024 | 4 | Filing |